Initial intravascular ultrasound without a routine early baseline study in the evaluation of cardiac transplant vasculopathy has prognostic valve

Reza Arsanjani, Avinash Khitri, Mehrnoosh Hashemzadeh, Mohammad R Movahed

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Abnormal minimal intimal thickening (MIT) on intravascular ultrasound (IVUS) defined as difference of ≥0.5 mm between baseline and one-year post-transplantation has been shown to have prognostic value. The goal of this retrospective cohort study was to evaluate whether abnormal MIT found on routine IVUS studies in cardiac transplant patients after 6 months without an early baseline study (modified MIT or MMIT), has any prognostic value. Furthermore, we evaluated the prognostic effect of serial IVUS performed beyond one year. Methods: A cohort of 149 cardiac transplant patients who underwent IVUS examination > 6 months post-transplant were evaluated retrospectively. Of these 149 patients, 109 patients underwent a subsequent IVUS study approximately 1 year following the initial study. MMIT values of ≥0.5 mm without an early baseline study were correlated with major adverse cardiac event (MACE). Results: The all-cause mortality was 4.7% (5/107) in patients with MMIT of <0.5 mm vs. 14.6% (6/41) in patients with MMIT of ≥0.5 mm [hazards ratio (HR): 3.2; 95% confidence interval (CI): 1.002–12.17; p = 0.039]. The overall MACE rate was 8.4% (9/107) in patients with MMIT of <0.5 mm vs. 24.4% (10/41) in patients with MMIT of ≥0.5 mm [HR: 6.7; 95% CI: 1.30–9.42; p = 0.009]. After adjusting for age, abnormal MMIT remained a significant independent predictor of MACE (HR: 3.93; CI 1.21–12.81; p = 0.023). Conclusions: The presence of abnormal MMIT noted on IVUS performed after 6 months post-transplantation without a routine baseline IVUS carries important prognostic value.

Original languageEnglish (US)
JournalCardiovascular Revascularization Medicine
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Transplants
Tunica Intima
Confidence Intervals
Transplantation
Cohort Studies
Retrospective Studies
Mortality

Keywords

  • Atherosclerosis
  • Cardiac transplant
  • Intravascular ultrasound
  • IVUS
  • Rejection
  • Transplant
  • Transplant vasculopathy
  • Transplantation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{7c519eb3ff354871a3c5e6dc8039e6e0,
title = "Initial intravascular ultrasound without a routine early baseline study in the evaluation of cardiac transplant vasculopathy has prognostic valve",
abstract = "Background: Abnormal minimal intimal thickening (MIT) on intravascular ultrasound (IVUS) defined as difference of ≥0.5 mm between baseline and one-year post-transplantation has been shown to have prognostic value. The goal of this retrospective cohort study was to evaluate whether abnormal MIT found on routine IVUS studies in cardiac transplant patients after 6 months without an early baseline study (modified MIT or MMIT), has any prognostic value. Furthermore, we evaluated the prognostic effect of serial IVUS performed beyond one year. Methods: A cohort of 149 cardiac transplant patients who underwent IVUS examination > 6 months post-transplant were evaluated retrospectively. Of these 149 patients, 109 patients underwent a subsequent IVUS study approximately 1 year following the initial study. MMIT values of ≥0.5 mm without an early baseline study were correlated with major adverse cardiac event (MACE). Results: The all-cause mortality was 4.7{\%} (5/107) in patients with MMIT of <0.5 mm vs. 14.6{\%} (6/41) in patients with MMIT of ≥0.5 mm [hazards ratio (HR): 3.2; 95{\%} confidence interval (CI): 1.002–12.17; p = 0.039]. The overall MACE rate was 8.4{\%} (9/107) in patients with MMIT of <0.5 mm vs. 24.4{\%} (10/41) in patients with MMIT of ≥0.5 mm [HR: 6.7; 95{\%} CI: 1.30–9.42; p = 0.009]. After adjusting for age, abnormal MMIT remained a significant independent predictor of MACE (HR: 3.93; CI 1.21–12.81; p = 0.023). Conclusions: The presence of abnormal MMIT noted on IVUS performed after 6 months post-transplantation without a routine baseline IVUS carries important prognostic value.",
keywords = "Atherosclerosis, Cardiac transplant, Intravascular ultrasound, IVUS, Rejection, Transplant, Transplant vasculopathy, Transplantation",
author = "Reza Arsanjani and Avinash Khitri and Mehrnoosh Hashemzadeh and Movahed, {Mohammad R}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.carrev.2019.01.028",
language = "English (US)",
journal = "Cardiovascular Revascularization Medicine",
issn = "1553-8389",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Initial intravascular ultrasound without a routine early baseline study in the evaluation of cardiac transplant vasculopathy has prognostic valve

AU - Arsanjani, Reza

AU - Khitri, Avinash

AU - Hashemzadeh, Mehrnoosh

AU - Movahed, Mohammad R

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Abnormal minimal intimal thickening (MIT) on intravascular ultrasound (IVUS) defined as difference of ≥0.5 mm between baseline and one-year post-transplantation has been shown to have prognostic value. The goal of this retrospective cohort study was to evaluate whether abnormal MIT found on routine IVUS studies in cardiac transplant patients after 6 months without an early baseline study (modified MIT or MMIT), has any prognostic value. Furthermore, we evaluated the prognostic effect of serial IVUS performed beyond one year. Methods: A cohort of 149 cardiac transplant patients who underwent IVUS examination > 6 months post-transplant were evaluated retrospectively. Of these 149 patients, 109 patients underwent a subsequent IVUS study approximately 1 year following the initial study. MMIT values of ≥0.5 mm without an early baseline study were correlated with major adverse cardiac event (MACE). Results: The all-cause mortality was 4.7% (5/107) in patients with MMIT of <0.5 mm vs. 14.6% (6/41) in patients with MMIT of ≥0.5 mm [hazards ratio (HR): 3.2; 95% confidence interval (CI): 1.002–12.17; p = 0.039]. The overall MACE rate was 8.4% (9/107) in patients with MMIT of <0.5 mm vs. 24.4% (10/41) in patients with MMIT of ≥0.5 mm [HR: 6.7; 95% CI: 1.30–9.42; p = 0.009]. After adjusting for age, abnormal MMIT remained a significant independent predictor of MACE (HR: 3.93; CI 1.21–12.81; p = 0.023). Conclusions: The presence of abnormal MMIT noted on IVUS performed after 6 months post-transplantation without a routine baseline IVUS carries important prognostic value.

AB - Background: Abnormal minimal intimal thickening (MIT) on intravascular ultrasound (IVUS) defined as difference of ≥0.5 mm between baseline and one-year post-transplantation has been shown to have prognostic value. The goal of this retrospective cohort study was to evaluate whether abnormal MIT found on routine IVUS studies in cardiac transplant patients after 6 months without an early baseline study (modified MIT or MMIT), has any prognostic value. Furthermore, we evaluated the prognostic effect of serial IVUS performed beyond one year. Methods: A cohort of 149 cardiac transplant patients who underwent IVUS examination > 6 months post-transplant were evaluated retrospectively. Of these 149 patients, 109 patients underwent a subsequent IVUS study approximately 1 year following the initial study. MMIT values of ≥0.5 mm without an early baseline study were correlated with major adverse cardiac event (MACE). Results: The all-cause mortality was 4.7% (5/107) in patients with MMIT of <0.5 mm vs. 14.6% (6/41) in patients with MMIT of ≥0.5 mm [hazards ratio (HR): 3.2; 95% confidence interval (CI): 1.002–12.17; p = 0.039]. The overall MACE rate was 8.4% (9/107) in patients with MMIT of <0.5 mm vs. 24.4% (10/41) in patients with MMIT of ≥0.5 mm [HR: 6.7; 95% CI: 1.30–9.42; p = 0.009]. After adjusting for age, abnormal MMIT remained a significant independent predictor of MACE (HR: 3.93; CI 1.21–12.81; p = 0.023). Conclusions: The presence of abnormal MMIT noted on IVUS performed after 6 months post-transplantation without a routine baseline IVUS carries important prognostic value.

KW - Atherosclerosis

KW - Cardiac transplant

KW - Intravascular ultrasound

KW - IVUS

KW - Rejection

KW - Transplant

KW - Transplant vasculopathy

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=85061209822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061209822&partnerID=8YFLogxK

U2 - 10.1016/j.carrev.2019.01.028

DO - 10.1016/j.carrev.2019.01.028

M3 - Article

AN - SCOPUS:85061209822

JO - Cardiovascular Revascularization Medicine

JF - Cardiovascular Revascularization Medicine

SN - 1553-8389

ER -